Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3881_Библиотеки_им_академика_М_И_Перельмана
.pdf
131
123. Hepatic intra-arterial injection of drug-eluting bead, irino-
tecan (DEBIRI) in
unresectable colorectal liver metastases refractory to systemic chemotherapy: results
of multi-institutional study / R.C. Martin, J. Joshi, K. Robbins [et al.] // Ann. Surg.
Oncol. – 2011. – Vol. 18. – P. 192-198.
124. Heterogeneity in Colorectal Primary Tumor and Synchronous Liver Metastases /
V.P. Shubin, A.A. Ponomarenko, A.S. Tsukanov [et al.] // Russ J. Genet. – 2018. –
Vol. 54, № 6. – P. 698-702.
125. Impact of preventive administration of antiemetic drugs on risk of acute nausea and
vomiting induced by transcatheter arterial chemoembolization in patients with
hepatocellular carcinomas – a retrospective study / M. Kabuki, H. Higashihara,
M. Kakuda [et al.] // Gan To Kagaku Ryoho. – 2013. – Vol. 40, № 2. – P. 197-120.
126. Impact of primary (1°) tumor location on overall survival (OS) and progression-free
survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis
of CALGB/SWOG 80405 (Alliance) / A.P. Venook, D. Niedzwiecki, F.
Innocenti
[et al.] // J. Clin. Oncol. – 2016. – Vol. 34. – P. 3504.
127. Improved overall survical with oxaliplatin, fluorouracil, and leucovarin
as adjuvant
treatment in stage II or III colon cancer in the MOSAIC trial / T. Andre, C. Boni, M.
Navarro [et al.] // J. Clin. Oncol. – 2009. – Vol. 27, № 19. – P. 3109-3116.
128. Improving respectability of hepatic colorectal metastases: expert consensus
statement / E.K. Abdalla, R. Adam, A.J. Bilchik [et al.] // Ann. Surg. Oncol. – 2006.
– Vol. 13, № 10. – P. 1271-1280. – doi: 10.1245/s10434-006-9045-5.
129. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus
intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final
results of a phase III study / G. Fiorentini, C. Aliberti, M. Tilli [et al.] // Anticancer
Res. – 2012. – Vol. 32, № 4. – P. 1387-1395 [Erratum appears in Anticancer Res. –
2013. – Vol. 33, № 11. – P. 5211].
130. Intra-arterial therapies for unresectable and chemorefractory colorectal cancer liver
metastases: a systematic review and meta-analysis. International Hepato-Pancreato-
Biliary Association Inc. Published by Elsevier Ltd. All rights reserved / J. Levy, J.
Zuckerman, R. Garfinkle [et al.] // HPB. – 2018. – Vol. 20. – P. 905-915.
132
131. Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-
institutional Analysis of 1497 Patients / J. Gagnière, A. Dupré, S.S. Gholami [et al.]
// Ann. Surg. – 2020. – Vol. 271. – P. 147-154.
132. Ischemic complications of transcatheter arterial chemoembolization in liver
malignancies / P.G. Tarazov, V.N. Polysalov, K.V. Prozorovskij [et al.] // Acta
Radiol. – 2000. – Vol. 41, № 2. – P. 156-160.
133. Johdi, N.A. Colorectal Cancer Immunotherapy: Options and Strategies / N.A.
Johdi,
N.F. Sukor // Front Immunol. – 2020. – Vol. 11. – P. 1624. –
doi: 10.3389/fimmu.2020.01624.
134. Kemeny, N. The management of resectable and unresectable liver metastases from
colorectal cancer / N. Kemeny // Currentopinioninoncology. – 2010. – Vol. 22. – P.
364-373.
135. Kurup, A.N. Ablation of musculoskeletal metastases: pain palliation, fracture risk
reduction, and oligometastatic disease / A.N. Kurup, M.R. Callstrom // Tech. Vasc
.
Interv. Radiol. – 2013. – Vol. 16, № 4. – P. 253-261.
136. Lencioni, R. Modified RECIST (mRECIST) assessment for hepatocellular
carcinoma / R. Lencioni, J.M. Llovet // Semin. Liver. Dis. – 2010. – Vol. 30, № 1.
– Р. 52-60.
137. Mahnken, A.H. Interventional Oncologic Approaches to Liver Metastases /
A.H. Mahnken, P.L. Pereira, T. de Baère // Radiology. – 2013. – Vol. 266, № 2. –
P. 407-430.
138. Management of end hole in placement of port-catheter sys- tem for continuous
hepatic arterial infusion chemo- therapy using the fixed catheter tip method /
T. Yamagami, T. Kato, S. Iida [et al.] // Am. J. Roentgenol. – 2005. – Vol. 184. –
P.
1332-1339.
139. Metaanalysis of transcatheter arterial chemoembolization plus radiofrequency
ablation versus transcatheterarterial chemoembolization alone for hepatocellular
carcinoma / D.J. Yang, K.L. Luo, H. Liu [et al.] // Oncotarget. – 2017. – Vol. 8, № 2.
– P. 2960-2970. – doi:10.18632/oncotarget.13813.
133
140. Metachronous metastases from colorectal cancer: a population-
based study in
North-East Netherlands / M.A. Elferink, K.P. de Jong,
J.M. Klaase [et al.] // Int. J.
Colorectal Dis. – 2015. – Vol. 30. – P. 205-212.
141. Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency
Microsatellite Instability as a Prognostic Factor / K. Fujiyoshi, G. Yamamoto,
T. Takenoya [et al.] // Anticancer Res. – 2017. – Vol. 37, № 1. – P. 239-247. –
doi: 10.21873/anticanres.11313.
142. Meyerhardt, J. Рак толстой кишки / J. Meyerhardt, M. Saunders; пер. с англ. –
Москва: ООО «Рид Элсивер», 2009. – 186 с.
143. Muller, M.F. Molecular pathological classification of colorectal cancer /
M.F. Muller, A.E.K. Ibrahim, M.J. Arends // Virchows Arch. – 2016. – Vol. 469, №
2. – P. 125-134.
144. National Comprehensive Cancer Network Colon cancer (version 4.2020). – 2020. –
URL: https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf (да
та обращения 22.05.2022 г.).
145. NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0. – 2017. –
URL: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/C
TCAE_v5_Quick_Reference_8.5x11.pdf (дата обращения 22.05.2022 г.).
146. Oxaliplatin as adjuvant therapy for colon cancer: updated result of NSABP C-07
trial, including survival and subset analyses / G. Yother, M.J. O’Connell,
C.J. Allerga [et al.] // J. Clin. Oncol. – 2011. – Vol. 29, № 28. – P. 3768-3774.
147. Pan-Asian adapted ESMO consensus guidelines for the management of patients with
metastatic colorectal cancer: A JSMO-
ESMO initiative endorsed by CSCO, KACO,
MOS, SSO and TOS / T. Yoshino, D. Arnold, H. Taniguchi [et al.] // Ann. Oncol. –
2018. – Vol. 29. – P. 44-70.
148. Pawlik, T.M. Surgical therapy for colorectal metastases to the liver / T.M. Pawlik,
M.A. Choti // J. Gastrointest Surg. – 2007. – Vol. 11. – P. 1057-1077.
149.
Phase II study on hepatic arterial infusion chemotherapy using percutaneous catheter
placement techniques for liver metastases from colorectal cancer (JFMC28 study) /
134
Y. Arai, T. Aoyama, Y. Inaba [et al.] // Asia Pac. J. Clin. Oncol. – 2015. –
Vol. 11,
№ 1. – P. 41-48.
150. Phase II trial of chemoembolization for the treatment of metastatic colorectal
carcinoma to the liver and review of the literature / C. Tellez, A.B. Benson 3rd, M.T.
Lyster [et al.] // Cancer. – 1998. – Vol. 82, № 7. – P. 1250-1259. –
doi: 10.1002/(sici)1097-0142(19980401)82:7<1250::aid-cncr7>3.0.co;2-j.
151. Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver
Metastases Varies According to Primary Colorectal Tumor Location / K. Sasaki,
G.A. Margonis, A. Wilson [et al.] // Ann. Surg. Oncol. – 2016. – Vol. 23. – P. 3736-
3743.
152. Prognostic role of braf mutations in colorectal cancerliver metastases / E. Pikoulis,
G.A. Margonis, N. Andreatos [et al.] // Anticancer Res. – 2016. – Vol. 36, № 9. – P.
4805-4811. – doi: 10.21873/anticanres.11040.
153. Prognostic value of resection of primary tumor in patients with stage IV colorectal
cancer: retrospective anaysis of two randomized studies and a review of the literature
/ S. Venderbosch, J.H. de Wilt, S. Teerenstra [et al.] // Ann. Surg. Oncol. – 2011. –
Vol. 18, № 12. – P. 3252-3260. – doi: 10.1245/s10434-011-1951-5.
154. Prophylactic topically applied ice to prevent cutaneous complications of nontarget
chemoembolization and radioembolization / D.S. Wang, J.D. Louie, N. Kothary
[et al.] // J. Vasc. Interv. Radiol. – 2013. – Vol. 24, № 4. – P. 596-600. –doi:
10.1016/
j.jvir.2012.12.020.
155. Prospective study on the survival of HCC patients treated with transcatheter arterial
lipiodol chemoembolization / Y.M. Mao, Z.Y. Luo, B. Li [et al.] // Asian Pac. J.
Cancer Prev. – 2012. – Vol. 13, № 3. – P. 1039-1042.
156. Pulmonary lipiodol embolism after transcatheter arterial chemoembolization for
hepatocellular carcinoma: a case report and literature review / T. Naorungroj,
T. Naksanguan, Y. Chinthammitr [et al.] // J. Med. Assoc. Thai. – 2013. – Vol. 96,
Suppl. 2. – P. 270-275.
157. Radiofrequency ablation combined with hepatic arterial chemoembolization using
degradable starch microsphere mixed with mitomycin C for thetreatment of liver
135
metastasis from colorectal cancer: a prospective multicenter study / K. Yamakado,
Y. Inaba, Y. Sato [et al.] // Cardiovascinterventiradiol. – 2017. – Vol. 40, № 4. –
P. 560-567.
158. Rashidian, N. Cancers Metastatic to the Liver / N. Rashidian, A. Alseidi, R.C. Kirks
// Surg. Clin. North Am. – 2020. – Vol. 100, № 3. – P. 551-563. –
doi: 10.1016/j.suc.2020.02.005.
159. Regional Therapies for Colorectal Liver Metastases: Systematic Review and
Clinical Practice Guideline / P. Karanicolas, J.R. Beecroft, R. Cosby [et al.] // Clin.
Colorectal. Cancer. – 2021. – Vol. 20, № 1. – P. 20-28. – doi: 10.1016/j.clcc.
2020.09.008.
160. Regional variations in UK colorectal cancer screening and mortality / A.T. George,
S. Aggarwal, S. Dharmavaram [et al.] // Lancet. – 2020. – Vol. 392. – P. 277-278. –
doi: 10.1016/S0140-6736(18)31208-X.
161. Repeated transarterial chemoembolisation using different chemotherapeutic drug
combinations followed by MR-guided laser-induced thermotherapy in patients with
liver metastases of colorectal carcinoma / T.J. Vogl, A. Jost, N.A. Nour-Eldin [et
al.] // Br. J. Cancer. – 2012. – Vol. 106. – P. 1274-1279.
162. Royer, R.J. Mechanism of Adverse Drug Reactions: An Overview / R.J. Royer //
Pharmacoepidemiology and drug safety. – 1997. – № 3. – Р. 43-50.
163. Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in
transarterial chemoembolization (TACE) for hepatocellular carcinoma / K. Okabe,
T. Beppu, K. Haraoka [et al.] // Anticancer Res. – 2011. – Vol. 31, № 9. – P. 2983-
2988.
164. Sasson, A.R. Surgical treatment of liver metastases / A.R. Sasson, E.R. Sigurdson //
Semin Oncol. – 2002. – Vol. 29, № 2. – P. 107-118. – doi: 10.1053/sonc.
2002.31676.
165. Scholefield, J. Колоректальный рак. Диагностика и тактика лечения /
J. Scholefield, C. Eng; пер. с англ.; под ред. Ю.А. Шелыгина. – Москва:
«Практическая медицина», 2019. – P. 175-186.
136
166. SEER Cancer Statistics / N. Howlader, A. Noone, M. Krapcho [et al.]. –
URL: https://seer.cancer.gov/csr/1975_2017/ (дата обращения: 26.05.2021 г.).
167. Selective hepatic artery embolization for treatment of patients with metastatic
carcinoid and pancreatic endocrine tumors / J.R. Strosberg, J. Choi, A.B. Cantor [et
al.] // Cancer Control. – 2006. – Vol. 13, № 1. – P. 72-78.
168. Setaffy, L. Microsatellite instability in colorectal cancer: clinicopathological
significance / L. Setaffy, C. Langner // Pol. J. Pathol. – 2015. – Vol. 66, № 3. –
P. 203-218. – doi: 10.5114/pjp.2015.54953.
169. Side Effect/Complication Risk Related to Injection Branch Level of
Chemoembolization in Treatment of Metastatic Liver Lesions from Colorectal
Cancer / M. Szemitko, E. Golubinska-Szemitko, E. Wilk-Milczarek, A. Falkowski
[et al.] // J. Clin. Med. – 2020. – Vol. 10, № 1. – P. 121. – doi: 10.3390/
jcm10010121.
170. Siegel, R.L. Cancer statistics, 2018 / R.L. Siegel, K.D. Miller, A. Jemal // CA.
Cancer. J. Clin. – 2018. – Vol. 68. – Р. 7-30.
171. Siegel, R.L. Cancer statistics, 2019 / R.L. Siegel, K.D. Miller, A. Jemal // CA Cancer
J. Clin. – 2019. – Vol. 69. – P. 7-34. – doi: 10.3322/caac.21551.
172. Surgery and preopera-
tive irradiation for locally advanced or reccurent rectal cancer
in patients over 75 years of age / S.G. Larsen, J.N. Wiig, S. Tretli [et al.] // Colorectal
Dis. – 2006. – Vol. 8, № 3. – P. 177-185.
173. Survival, safety, and prognostic factors for outcome with Regorafenib in patients
with metastatic colorectal cancer refractory to standard therapies: results from a
multicenter study (REBECCA) nested within a compassionate use program /
A. Adenis, C. de la Fouchardiere, B. Paule [et al.] // BMC Cancer. – 2016. – Vol. 16,
№ 7. – P. 412-420. – doi: 10.1186/s12885-016-2440-9.
174. Systematic review of randomized and nonrandomized trials of the clinical response
and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver
metastases / T.C. Chua, A. Saxena, W. Liauw [et al.] // Ann. Surg. Oncol. – 2010. –
Vol. 17, № 2. – P. 492-501. – doi: 10.1245/s10434-009-0781-1.
137
175. Thalamic and midbrain infarct during transarterial chemoembolization of
hepatocellular carcinoma / R. Kumar, S.M. Hassan, A. Zaigham [et al.] // J. Pak.
Med. Assoc. – 2012. – Vol. 62, № 3. – P. 295-297.
176. The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use
of Irinotecan-Loaded Chemoembolisation in Colorectal Cancer Liver Metastases:
Interim Analysis / P.L. Pereira, R. Iezzi, R. Manfredi [et al. // Cardiovasc. Intervent
Radiol. – 2021. – Vol. 44, № 1. – P. 50-62. – doi: 10.1007/s00270-020-02646-8.
177. The role of hepatic trans-
arterial chemoembolization in metastatic medullary thyroid
carcinoma: a specialist center experience and review of the literature / S. Grozinsky-
Glasberg, A.I. Bloom, N. Lev-Cohain [et al.] // Eur. J. Endocrinol. – 2017. – Vol.
176. – P. 463-470.
178. The role of interventional oncology in the treatment of colorectal cancer liver
metastases / M. Tsitskari, D. Filippiadis, C. Kostantos [et al.] // Ann. Gastroenterol.
– 2019. – Vol. 32, № 2. – P. 147‐155. – doi: 10.20524/aog.2018. 0338.
179. The significance of transarterial chemoembolization combined with systemic
chemotherapy for patients with KRAS wildtype unresectable metachronous
colorectal carcinoma with liver metastases / Q. Yu, L. Zhang, S. Fan
[et al.] //
J. Cancer Res. Ther. – 2016. – Vol. 12, Suppl. – P. C205-C11.
180. Third-
line treatment of colorectal liver metastases using DEBIRI
chemoembolization / G. Scevola, G. Loreni, M. Rastelli [et al.] // Med. Oncol. –
2017. – Vol. 34. – P. 37.
181.
Transarterial chemoembolization: Evidences from the literature and applications in
hepatocellular carcinoma patients / A. Facciorusso, R. Licinio, N. Muscatiello
[et al.] // World J. Hepatol. – 2015. – Vol. 7. – P. 2009-2019.
182. Transarterial chemoembolization of unresectable hepatocellular carcinoma with
drug eluting deads: Result of an openlabel study of 62 patient / K. Malagari,
K. Chatzimichael, E. Alexopoulou [et al.] // Cardiovasc. Intervent. Radiol. –
2008.
– Vol. 31, № 2. – P. 269-280.
183.
Transarterial chemoembolization of unresectable systemic chemotherapy refractory
liver metastases: a retrospective single-center analysis / Y. Ren, L. Chen, S. Huang
138
[et al.] // Abdom Radiol. – 2020. – Vol. 45. – P. 2862-2870. – doi: 10.1007/s00261-
020-02584-6.
184. Transarterial (chemo) embolisation versus chemotherapy for colorectal cancer liver
metastases / M.M. Bala, J.W. Mituś, R.P. Riemsma [et al.] // Cochrane Database
Syst. Rev. – 2017. – Vol. 8. – P. CD012757. – doi: 10.1002/14651858.CD012757
185. Transarterial chemoembolization with irinotecan-loaded drug- eluting beads
(DEBIRI) and capecitabine in refractory liver prevalent colorectal metastases: a
phase ii single-center study / R. Iezzi, V.A. Marsico, A. Guerra [et al.] // Cardiovasc.
Intervent. Radiol. – 2015. – Vol. 38. – P. 1523-1531.
186. Transarterial therapies for hepatocellular carcinoma / B. Sangro, D. D’Avola,
M. Iarrairaegui, J. Prieto // Expert Opin Pharmacother. – 2011. – Vol. 12, № 7. –
P. 1057-1073.
187. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic /
R. Lencioni, X.P. Chen, L. Dagher, A.P. Venook // Oncologist. – 2010. –
Vol. 15,
Suppl. 4. – P. 42-52.
188. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FoLFIRInoX):
a phase II study in colorectal cancer patients with non- resectable liver metastases
/
M. Ychou, F. Viret, A. Kramar [et al.] // Cancer Chemother. Phar- macol. – 2008. –
Vol. 62, № 2. – P. 195-201.
189. Yancik, R. Cancer burden in the aged: an epidemiologic and demographic overview
/ R. Yancik // Cancer. – 1997. – Vol. 80, № 7. – P.1273-1283.
139
ПРИЛОЖЕНИЕ
Приложение А
(справочное)
Схема осложнений химиоэмболизации печеночной артерии
140
Приложение Б
(справочное)
Патент № 2800325
Соседние файлы в папке Библиотека им академика М.И. Перельмана